BT-409

About Brenig Therapeutics

Brenig Therapeutics is a private, preclinical-stage biotech founded in 2021 by a consortium of leading life science investors. The company is developing a pipeline of brain-penetrant small molecules, led by BT-267, a selective LRRK2 inhibitor for Parkinson's disease that has completed a Phase 1 study. Brenig leverages AI and machine learning in its drug discovery process to design highly selective compounds with optimized CNS exposure, aiming to build a portfolio of first- and best-in-class therapies for neurodegenerative disorders.

Therapeutic Areas